Rhinitis, Allergic, Seasonal
Conditions
Keywords
Ragweed, Allergy, Allergic, Rhinitis, Hay Fever, Seasonal, Treatment, Immunotherapy, Vaccine
Brief summary
The purpose of this study is to find out if a new investigational vaccine, TOLAMBA™, is safe and effective in reducing the symptoms of ragweed allergy.
Detailed description
Ragweed allergy is the most common seasonal allergy in North America. Allergen immunotherapy is a therapeutic option for patients who have allergy symptoms that cannot be adequately controlled by avoidance of the allergen or medication. It may also be appropriate for those who cannot tolerate their medications due to side effects or have difficulties with medication compliance. This study compares the safety and efficacy of two different dosing regimens of TOLAMBA™ with placebo in reducing the symptoms of ragweed-allergic adults over two consecutive ragweed pollen seasons. Comparison(s): Subject-rated allergy symptoms of subjects treated with TOLAMBA™ dose-intense regimen or TOLAMBA™ lower-dose regimen, compared with subjects treated with placebo.
Interventions
BIOLOGICALAmb a 1 immunostimulatory oligodeoxyribonucleotide conjugate
Escalating doses, 6 weekly subcutaneous (under the skin) injections
BIOLOGICALHistamine base
Escalating doses, 6 weekly subcutaneous (under the skin) injections
Sponsors
Dynavax Technologies Corporation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Has a history of ragweed allergic rhinitis (hayfever) during at least the last 2 consecutive seasons that has required treatment with antihistamines, decongestants and/or nasal steroids, but where symptom relief has been incomplete * Is willing to stay in their ragweed area during the historical peak period of the local ragweed season, and willing to travel for no more than 2 weeks (cumulative time) outside of their ragweed area during the entire season
Exclusion criteria
* Has had any hospital admissions for asthma * Has smoked within the past year, or has a ≥10-pack per year smoking history * Has had any previous immunotherapy with ragweed pollen extract, or was in a previous clinical trial with TOLAMBA™ * Has used Xolair within the past 12 months * Has a history of anaphylaxis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in total nasal symptom score during the peak period of the ragweed pollen season. | Two years |
Countries
United States
Outcome results
None listed